



FOR IMMEDIATE RELEASE

**Merrimack Pharmaceuticals Names Lisa Evrén
Senior Vice President and Chief Financial Officer**

Cambridge, MA – June 26, 2007. Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for autoimmune disease and cancer, today announced that Lisa Evrén has joined Merrimack as Senior Vice President and Chief Financial Officer.

Ms. Evrén joins Merrimack from Amgen, Inc., where she was Vice President and Treasurer from 2002 to 2007. In that capacity, she was responsible for capital raising, investment, and associated P&L, balance sheet and risk management. Prior to Amgen, Ms. Evrén held senior finance positions at Sun Microsystems, Inc., Hewlett-Packard Company and Pfizer Inc. Ms. Evrén holds a BA from Pomona College, a JD and LL.M (Taxation) from the New York University School of Law, and is also a registered nurse.

“Lisa Evrén joins Merrimack at an important stage, as we advance our MM-093 clinical development programs in autoimmune disease and prepare to initiate clinical development of MM-121, our lead cancer product discovered using our proprietary Network Biology platform,” said Robert Mulroy, President and CEO of Merrimack Pharmaceuticals. “Lisa has proven capabilities as a top executive while bringing outstanding skills in financial management as well as a track record of success across a broad range of transactions. Lisa will be a valuable asset to Merrimack as we continue to build a world-class biopharmaceutical company.”

“I am excited to have the opportunity to contribute to the growth and development of an entrepreneurial company on the leading edge of pharmaceutical research and development,” said Ms. Evrén. “We will build on Merrimack’s strong financial foundation to support the expanded breadth and depth of our clinical and research efforts.”

Merrimack Pharmaceuticals, Inc., is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis, psoriasis or with autoimmune uveitis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit <http://www.merrimackpharma.com>.

Contact: Kathleen Petrozzelli, Manager, Corporate Communications, 617-441-1043